# Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer

> **NCT05896865** · NA · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer Stage III

## Interventions

- **RADIATION:** Whole breast / chest wall & regional lymph node irradiation
- **RADIATION:** Internal mammary or supraclavicular lymph node boost

## Key facts

- **NCT ID:** NCT05896865
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-16
- **Primary completion:** 2028-03-16
- **Final completion:** 2030-03-16
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896865, "Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05896865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*